Nanovis Named MedTech Outlook Top 10 Orthopedic Solution Provider, 2019

Wednesday, May 8, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Company recognized for its nanotechnology-based spinal devices

CARMEL, Ind., May 8, 2019 /PRNewswire-PRWeb/ -- Nanovis today announced that MedTech Outlook recognized Nanovis as

a Top 10 Orthopedic Solution Provider, 2019.

MedTech Outlooks annual awards recognize innovative companies in the Orthopedic industry.

"A distinguished panel of CMIOs, CIOs, analysts, and venture capitalists, along with the editorial panel of Med Tech Outlook has selected Nanovis as a Top 10 Orthopedic Solution Provider, 2019," said Alex D'souza, Managing Editor of Med Tech Outlook. "We congratulate Nanovis for being at the forefront of providing cutting-edge infection technology solutions; the value these solutions offer to surgeons and hospitals is evident. We anticipate hearing more about the success of Nanovis in the years to come."

"Nanovis is honored to be recognized by MedTech Outlook," says Nanovis CEO Matt Hedrick. "Recognition of our technology platforms for fixation and infection is an honor that our scientists and our surgeon collaborators are grateful to accept."

Nanovis' fixation technology platforms continue to perform well commercially and in testing. The FortiCore interbody system with a deeply porous titanium scaffold, intermolded with a PEEK core is attractive to surgeons who want deep porosity and the visualization and modulus benefits of PEEK. Nanovis will soon reveal favorable testing results from comparison tests of their nanotube-bioceramic surface compared to non-nanorough titanium, acid-etched nanorough titanium and calcium phosphate coated titanium.

Nanovis is a platform technology-driven growth company committed to helping surgeons and hospitals achieve excellent fixation and infection outcomes using advanced nanotechnology platforms. Its industry-leading fixation technologies offer surgeons and hospitals the best aspects of fixation, visualization, and durability. Nanovis' developmental infection technology platforms promise to offer surgeons and hospitals much-needed bactericidal solutions

For information about distribution opportunities, please contact Jeff Shepherd, Vice President of Sales, at jeff.shepherd@nanovistechnology.com.

About Nanovis

Nanovis' mission is to develop science-enhanced, life-improving technologies. The Company's patented and proprietary regenerative technology platforms provide differentiated surface advantages enabling the potential for existing medical devices to achieve new outcomes. Focused on aggressive, sustainable growth across multiple markets, Nanovis is commercializing science-driven platforms: the deeply porous scaffold currently available with the FortiCoreŪ line of interbody fusion devices (deeply porous ti scaffold licensed from Sites Medical); an advanced nano-tube surface technology; a bactericidal surface technology in pre-clinical studies, and a localized infection technology targeted toward anti-microbial resistant bacteria in pre-clinical studies.

 

SOURCE Nanovis



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store